Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Trial details

Who runs it

Fox Chase Cancer Center

Trial code

NCT05400577

Record updated

17 July 2023

Original description

This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all. Patients must have been deemed surgically resectable and physiologically fit for surgery by a thoracic surgeon prior to enrollment.Read full original descriptionShow less

Neoadjuvant Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA Non-Small Cell Lung Cancer (NSCLC)

This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all. Patients must have been deemed surgically resectable and physiologically fit for surgery by a thoracic surgeon prior to enrollment.

Inclusion: Patients must have non-squamous NSCLC with KRAS G12C mutation identified through molecular testing (local assessment), AJCC 8 stages Ib, IIa, IIb, IIIa (single nodal station) and assessment by a thoracic surgeon that the patient is potentially resectable and physiologically operable. Lymph nodes should be pathologically staged, if feasible, prior to enrollment; No prior NSCLC anticancer therapy; Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 11.0; Age > 18 years; ECOG performance status 0 or 1; Must have the ability to take oral medications and willing to record daily adherence to investigational product utilizing a sponsor-provided dosing diary; Subjects must have normal organ and marrow function as defined below; Absolute neutrophil count > 1,000/mcL; Platelets > 75,000/mcL; Total bilirubin < 1.5 x ULN (< 2.0 x ULN for subjects with documented Gilbert's syndrome or < 3.0 x ULN for whom the indirect bilirubin level suggests an extrahepatic source of elevation); AST/ALT (SGOT/SGPT) < 2.5 times institutional normal limits; Creatinine clearance Estimated glomerular filtration rate based on MDRD (Modification of Diet in Renal Disease) calculation >=30 ml/min/1.73 m2; Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x ULN, OR International normalized ratio (INR) <1.5 or within target range if on anticoagulation therapy; Ability to understand and willingness to sign a written informed consent and HIPAA consent document.

Exclusion: Any prior therapy directed at NSCLC and Previous treatment with a direct KRAS G12C inhibitor; Patients receiving any other investigational agents; Patients receiving any medications or substances that are strong inhibitors or inducers of sotorasib ineligible. Please refer to section 5.2 for details about excluded therapies and restrictions; Major surgery (as assessed by treating clinician) within 28 days of study registration; Patients with uncontrolled intercurrent illness, that would in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, informed consent, procedures, primary endpoint or study completion. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with non-invasive malignancies (e.g. in situ cervical cancer) ARE eligible; History of allergic reactions attributed to compound of similar chemical or biologic composition to the agent used in this study; Pregnant or breast feeding. Refer to section 4.4 for further detail.

ClinicalTrials.gov NCT05400577